bluebird bio, Inc. (BLUE) News

bluebird bio, Inc. (BLUE)

Today's Latest Price: $65.12 USD

1.22 (-1.84%)

Updated Jul 9 2:10pm

Add BLUE to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 338 in Biotech

See all "A" rated Strong Buy stocks

Filter BLUE News Items

BLUE News Results

Event/TimeSymbolCompanyNews DetailStartEndChangePOWR Rating
Loading, please wait...

Latest BLUE News From Around the Web

Below are the latest news stories about bluebird bio Inc that investors may wish to consider to help them evaluate BLUE as an investment opportunity.

How Much Of bluebird bio, Inc. (NASDAQ:BLUE) Do Institutions Own?

The big shareholder groups in bluebird bio, Inc. (NASDAQ:BLUE) have power over the company. Insiders often own a large...

Yahoo | July 7, 2020

Wall Street Has Given Up on These 2 Stocks, and That's a Huge Mistake

For instance, Shopify (NYSE: SHOP) has been an expensive stock for years. StoneCo (NASDAQ: STNE) has unbelievably good numbers. In my mind, StoneCo is very similar to Square (NYSE: SQ), the fintech superstar in the U.S. Like Square, StoneCo is using technology to create a whole ecosystem of start-up retail entrepreneurs.

Yahoo | July 1, 2020

How bluebird bio (BLUE) Stock Stands Out in a Strong Industry

bluebird bio (BLUE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Yahoo | June 23, 2020

Repare and Forma Shares Gobbled Up in IPO

Both companies boosted price and number of shares in their offerings Continue reading...

Yahoo | June 22, 2020

Edited Transcript of BLUE.OQ earnings conference call or presentation 11-May-20 12:00pm GMT

Q1 2020 bluebird bio Inc Earnings Call

Yahoo | June 18, 2020

Bluebird and Crispr Show Promise for Sickle-Cell Cures

The new data on Crispr’s products prompts Canaccord Genuity analyst to raise her price target on the Buy-rated stock.

Yahoo | June 16, 2020

IPO Update: Forma Therapeutics Readies $200 Million IPO

Quick Take Forma Therapeutics Holdings (FMTX) intends to raise $200 million in an IPO of its voting common stock, per an amended registration statement. The company is developing a pipeline of drug candidates for the treatment of various hematologic (blood) diseases and cancers. FMTX has collaboration and investment relationships with...

Donovan Jones on Seeking Alpha | June 15, 2020

Bluebird bio gene therapy shows high response rate in beta thalassemia

Bluebird bio (BLUE) announces new data from ongoing Phase 3 clinical trials evaluating gene therapy Zynteglo (betibeglogene autotemcel) (formerly LentiGlobin) in adolescent and adult patients with a range of genotypes of transfusion-dependent beta-thalassemia ((TDT)).All 23 patients in the Phase 3 Northstar-2 study have been treated and followed for a median...

Seeking Alpha | June 12, 2020

Bluebird bio gene therapy shows positive action in sickle cell disease

Bluebird bio (BLUE) announces updated data from its ongoing Phase 1/2 clinical trial, HGB-206, evaluating gene therapy LentiGlobin in adolescents and adults with sickle cell disease ((SCD)). The results were virtually presented at EHA.At data cutoff, 37 patients had been treated. All patients (n=25) in Group C were able to...

Seeking Alpha | June 12, 2020

bluebird bio (BLUE) Presents At European Hematology Association Congress Conference - Slideshow

The following slide deck was published by bluebird bio, Inc. in conjunction with this event....

SA Transcripts | June 12, 2020

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7069 seconds.